FABP5 is overexpressed in prostatecancer and is associated with poor patient prognosis and survival.193 However, the identification of FABP5 as a moleculartarget for prostate cancer remains in its early stage, with severalchallenges to overcome, primarily due to the ubiquity of FABP5. Here, FABP5 is linked to prostate carcinoma.